MarketCap
Atea Pharmaceuticals AVIR
€ 3.78
-4.29%
Facebook
X
Telegram
Atea Pharmaceuticals Gesamtverbindlichkeiten | AVIR
Gesamtverbindlichkeiten Jährlich Atea Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.8 M | 25.8 M | 39.8 M | 26.1 M | 62.8 M | 316 M | 71.6 M | 71 M | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 316 M | 25.8 M | 81.6 M |
Gesamtverbindlichkeiten Vierteljährlich Atea Pharmaceuticals
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 39.8 M | 27.2 M | 27.2 M | 28.9 M | 25.8 M | 32.4 M | 33.9 M | 48.7 M | 39.8 M | 26.3 M | 23.7 M | 19.9 M | 26.1 M | 23.4 M | 33.9 M | 37.3 M | 62.8 M | 262 M | 274 M | 254 M | 316 M | 10.9 M | 316 M | 316 M | 2.53 M | 2.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 316 M | 2.53 M | 88.9 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Qualigen Therapeutics
QLGN
|
4.14 M | - | 5.59 % | $ 1.16 M |  USA |
 |
Qilian International Holding Group Limited
QLI
|
41.9 M | - | -6.08 % | $ 184 M |  China |
 |
Cassava Sciences
SAVA
|
44 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
423 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
74 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
5.17 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
4.31 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
4.1 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
22.9 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
28.7 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
15.3 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
2.66 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
85.9 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
169 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
25.4 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
58.4 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
14.7 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
1.27 B | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
42.8 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
1.07 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
1.84 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
46.8 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
4.81 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
29.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
3.51 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
64 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
135 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
50.4 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
65.9 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
97.3 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
3.76 B | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
78.6 M | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
283 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
159 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
345 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
483 K | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
14.4 M | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.7 M | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |